MI-BASiC: Non-diabetic patients have greater weight loss after surgeryDiabetes reduces the weight loss effect of bariatric surgery in the first three years after surgery, especially in those undergoing...
Tirzepatide has unique ability to stimulate insulin secretionTirzepatide (Mounjaro) has a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy...
More adolescents in the US are undergoing metabolic and bariatric surgeryMore adolescents in the US are undergoing metabolic and bariatric surgery (MBS), according to researchers from University of Texas Health...
AOMs help patients manage postsurgical weight recurrenceAnti-obesity medications, including semaglutide (Ozempic and Wegovy), can effectively help patients manage weight regained after...
Obesity will become the most important risk factor for heart attacksResearchers from the National University of Singapore have predicted that the number of heart attacks in Singapore is projected to rise...
FDA warns against using compounded semaglutideThe FDA has received adverse event reports after patients used compounded semaglutide for type 2 diabetes and weight loss. Drug...
Journal Watch 31/05/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...